He warned about the dangers of AI. If only his father had listened

Ben Riley had started a newsletter to help people make better decisions about when and how to use generative AI – but seemed ...
USA Today

Why AI Cancer Care Tools Must Be Developed With Patients and Advocates

As artificial intelligence (AI) tools continue to proliferate, they are becoming a go-to search tool for patients, providers, and caregivers. Blood cancer patients are using AI in oncology to help ...
cancerhealth

Mission Accomplished: One Woman’s Quest to Fully Understand Her Cancer Diagnosis

2008 is a year Albie Suozzi, 66, will never forget. It was the year her only son died in a motorcycle accident. Two weeks after that tragedy, she was diagnosed with chronic lymphocytic leukemia (CLL), ...
WebMD

Calquence Plus Venclexta: FDA Approves First All‑Oral Fixed‑Duration Regimen for Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

What Is It, and Why Does It Matter? The FDA has approved a new combination treatment for adults with certain cancers of the blood and lymphatic system. The targeted regimen combines Calquence ...
Healio

First all-oral, fixed-duration combination regimen wins FDA approval for untreated CLL

Please provide your email address to receive an email when new articles are posted on . The combination is the first all-oral, fixed duration treatment for patients with CLL and or small lymphocytic ...
MedPage Today

FDA OKs Novel Fixed-Duration Oral Combo for Untreated CLL

The FDA approved acalabrutinib (Calquence) plus venetoclax (Venclexta) for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma as the first all-oral, fixed-duration ...
Seeking Alpha

Jaypirca® (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, Now Available in Canada for Adult Patients with Relapsed or Refractory Mantle Cell ...

Mantle cell lymphoma (MCL) relapsed or refractory in patients who have previously received at least two lines of systemic therapy including a Bruton tyrosine kinase (BTK) inhibitor; or Chronic ...
Los Angeles Times

‘Second Winds’: A Journey of Resilience and Renewal

For many, it represents the worst day of their life: The day they receive a cancer diagnosis. Hearing the words ring from a physician’s mouth. Having the world fade away. The mind spinning with the ...
Medscape

Pirtobrutinib Improves PFS in Treatment-Naive CLL/SLL

Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...